Previous 10 | Next 10 |
- Dedicated Senior-Level Function will Enhance and Expand Existing Strategic IR Program Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene ed...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today received an upfront cash payment and...
2024-02-09 07:20:01 ET Precision BioSciences ( NASDAQ: DTIL ) Friday announced that its Board of Directors has approved a 1-for-30 reverse stock split of the company’s common stock to increase the per-share market price to meet the minimum per share bid price requirement fo...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that its Board of Dire...
2024-01-10 10:00:05 ET Summary TG Therapeutics CEO Mike Weiss recently presented at the J.P. Morgan Healthcare Conference, sharing positive updates on Briumvi's Q4 2023 net sales and revenue guidance for 2024. 2024 revenue guidance and the expense guidance suggest the company shou...
2024-01-09 10:16:00 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Seres Therapeutics Inc (NASDAQ: MCRB), Sentage Holdings (NASDAQ: SNTG), Precision BioSciences Inc (NASDAQ: DTI...
2024-01-09 09:42:05 ET A North Carolina-based biotech firm is turning heads so far Tuesday morning after it was announced a strategic transaction with TG Therapeutics Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and ot...
2024-01-09 07:55:05 ET Precision BioSciences ( NASDAQ: DTIL ) shares rallied 20% premarket on Tuesday after it entered into a $17.5M global licensing deal with with TG Therapeutic ( NASDAQ: TGTX ). Under the deal, TG Therapeutics ( TGTX ) will acquire a world...
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), “the Company,” today announced that it has entered into an agreement with Precision BioSciences , Inc. ( NASDAQ GS: DTIL) to acquire a worldwide license to Precision’s Azercabta...
- Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments - Upfront Cash and Near-Term Payments Expected to Extend Precision’s Cash Runway into the First Half of 2026 and Fund Precision...
News, Short Squeeze, Breakout and More Instantly...
Precision BioSciences Inc. Company Name:
DTIL Stock Symbol:
NYSE Market:
Precision BioSciences Inc. Website:
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading Healthcare Seaside Summit being held July 14...
2024-07-06 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russel...